Danish drug maker Novo Nordisk said on Thursday it will reduce the U.S. list prices of two insulin products by more than 70% ...

This system also means that insurers end up with different rates for each drug company, so a brand of insulin that has a minimal co-pay under one insurance could cost the full list price under ...

Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new ...

“Although not named in this case, all drug manufacturers should be ... adding that the company has not raised list prices for ...

Pharmaceutical giant Sanofi has capped the price of its insulin, becoming the last of three major manufacturers of the drug to curb soaring costs of the lifesaving medication in the US.